Apyx Medical Corp (APYX) Financial Statements (2026 and earlier)

Company Profile

Business Address 5115 ULMERTON ROAD
CLEARWATER, FL 33760
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29,30131,01131,74128,01332,67837,282
Cash and cash equivalent29,30131,01131,74128,01332,67837,282
Receivables11,24811,64515,48013,03612,70912,487
Inventory, net of allowances, customer advances and progress billings8,1927,6857,5649,0009,3249,795
Inventory8,1927,6857,5649,0009,3249,795
Other undisclosed current assets1,1741,5101,6552,1091,9602,362
Total current assets:49,91551,85156,44052,15856,67161,926
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization384348535964
Operating lease, right-of-use asset4,4644,5844,7034,8204,9355,049
Property, plant and equipment2,0481,9101,9871,9051,9181,779
Other noncurrent assets1,7231,7721,6641,7851,8111,893
Total noncurrent assets:8,2738,3098,4028,5638,7238,785
TOTAL ASSETS:58,18860,16064,84260,72165,39470,711
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,1689,13610,3669,2059,0188,117
Accounts payable2,8932,3052,6151,9142,3482,103
Accrued liabilities7,2756,8317,7517,2916,6706,014
Deferred revenue      515
Debt202020202020
Other undisclosed current liabilities3783543353301,6011,904
Total current liabilities:10,5669,51010,7219,55510,63910,556
Noncurrent Liabilities
Long-term debt and lease obligation34,38834,15533,92633,89133,67133,454
Long-term debt, excluding current maturities34,36534,12733,89333,85333,62833,406
Finance lease, liability232833384348
Liabilities, other than long-term debt5,7785,8515,8606,0786,1606,241
Deferred revenue1,1941,1941,1181,2711,2711,252
Other liabilities292270259201192194
Operating lease, liability4,2924,3874,4834,6064,6974,795
Total noncurrent liabilities:40,16640,00639,78639,96939,83139,695
Total liabilities:50,73249,51650,50749,52450,47050,251
Equity
Equity, attributable to parent7,25310,51114,21011,04114,74720,253
Common stock383838353535
Additional paid in capital93,05492,53492,08384,28983,29282,242
Accumulated deficit(85,839)(82,061)(77,911)(73,283)(68,580)(62,024)
Equity, attributable to noncontrolling interest203133125156177207
Total equity:7,45610,64414,33511,19714,92420,460
TOTAL LIABILITIES AND EQUITY:58,18860,16064,84260,72165,39470,711

Income Statement (P&L) ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Revenues11,3739,43014,22211,48712,14910,244
Cost of revenue
(Cost of Product and Service Sold)
(4,290)(3,765)(5,258)(4,533)(4,656)(4,295)
Gross profit:7,0835,6658,9646,9547,4935,949
Operating expenses(9,657)(8,716)(12,012)(10,589)(13,040)(12,564)
Other operating expense, net  (43,659)  (21)
Other expenses      
Other undisclosed operating income  43,659  21
Operating loss:(2,574)(3,051)(3,048)(3,635)(5,547)(6,615)
Nonoperating expense(1,115)(1,072)(1,522)(1,029)(989)(922)
Investment income, nonoperating278304294378  
Other nonoperating income (expense)   (163)24(989)(922)
Interest and debt expense(1,393)(1,376)(1,653)(1,431)(1,427)(1,396)
Loss from continuing operations before equity method investments, income taxes:(5,082)(5,499)(6,223)(6,095)(7,963)(8,933)
Other undisclosed income from continuing operations before income taxes1,3931,3761,6531,4311,4271,396
Loss from continuing operations before income taxes:(3,689)(4,123)(4,570)(4,664)(6,536)(7,537)
Income tax expense(49)(49)(89)(60)(50)(53)
Net loss:(3,738)(4,172)(4,659)(4,724)(6,586)(7,590)
Net income (loss) attributable to noncontrolling interest(40)2231213014
Net loss available to common stockholders, diluted:(3,778)(4,150)(4,628)(4,703)(6,556)(7,576)

Comprehensive Income ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Net loss:(3,738)(4,172)(4,659)(4,724)(6,586)(7,590)
Comprehensive loss:(3,738)(4,172)(4,659)(4,724)(6,586)(7,590)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(40)2231213014
Comprehensive loss, net of tax, attributable to parent:(3,778)(4,150)(4,628)(4,703)(6,556)(7,576)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: